Market News AIOpen the app

Neumora Therapeutics shared its financial results for the third quarter ending September 30, 2026.

ResultsRead the original at SEC EDGAR
Neutral

Neumora submitted an FDA application for NMRA-215 and reported up to 19% weight loss in mice, plus no serious side effects in an NMRA-511 study. But it had $85.7 million in cash and says it needs substantial new funding, so the updates do not clearly change its outlook.

NMRA · Neumora Therapeutics, Inc.

AI read · Neutral

The AI's read

The pipeline updates show progress, but they do not settle how well these treatments will work in people. NMRA-511's new results came from healthy older adults, and NMRA-215's weight-loss findings came from mice. Neumora also says it needs substantial new funding and gave no updated estimate of how long its cash will last. These facts leave no clear change in its outlook.

Get alerts for NMRA

Follow Neumora Therapeutics, Inc. (NMRA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NMRA
Free on the App Store and Google Play, or on the web.